HI
KRYS icon

Horizon Investments’s Krystal Biotech KRYS Stock Holding History

Horizon Investments’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.5K Sell
304
-108
-26% -$28.7K ﹤0.01% 1104
2025
Q4 		$102K Buy
+412
New +$86.7K ﹤0.01% 1058

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Horizon Investments's KRYS Position: Q1 2026 in Review

Horizon Investments reduced its Krystal Biotech (KRYS) stake by 26% in Q1 2026, selling an estimated $28.7K and leaving 304 shares worth $78.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1104.

Horizon Investments first reported a position in KRYS in Q4 2025 and has held it in 2 quarters since. The position peaked at $102K in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Horizon Investments held 304 shares of Krystal Biotech worth $78.5K as of Q1 2026.
  • Horizon Investments sold 108 Krystal Biotech shares in Q1 2026, an estimated $28.7K.
  • Krystal Biotech made up ﹤0.01% of Horizon Investments's portfolio in Q1 2026, its #1104 holding.
  • Horizon Investments first reported a position in Krystal Biotech in Q4 2025 and has held it in 2 quarters since.
  • Horizon Investments's Krystal Biotech position peaked at $102K in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Horizon Investments's 13F filing for Q1 2026, filed 15 May 2026.